Physician profile
Kyle Fortman
NPI 1598828923
$12,028.39
in general payments reported to CMS, 2019-2025
17 companies · $8,539 in 2025
The $8,539 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $583 · 2023: $444 · 2024: $2,263 · 2025: $8,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,900 · Food and Beverage: $3,828 · Travel and Lodging: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,900.00 |
| Food and Beverage | $3,828.24 |
| Travel and Lodging | $517.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $9,853.37 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Evoque |
| Abbott Laboratories | $564.80 | 2024-2025 | Ultreon, Amplatzer Talisman |
| Bayer Healthcare Pharmaceuticals INC. | $223.68 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $214.24 | 2021-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $181.66 | 2022 | |
| Boston Scientific Corporation | $170.07 | 2021-2025 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $154.03 | 2021-2023 | Xarelto |
| Atricure, INC. | $145.77 | 2025 | Atriclip Laa Exclusion System, Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax |
| Kestra Medical Technology Services, INC. | $115.08 | 2023 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $90.65 | 2021-2022 | |
| Esperion Therapeutics, INC. | $86.12 | 2023-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.16 | 2021-2023 | Jardiance |
| Abiomed | $65.29 | 2024-2025 | Impella |
| Pfizer INC. | $40.26 | 2021-2025 | |
| La Jolla Pharmaceutical Company | $17.94 | 2025 | Giapreza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.98 | 2021 | |
| Lemaitre Vascular, INC. | $14.29 | 2025 | Restoreflow |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Fortman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.